Showing results (11-20 of 48) with videos related to
Sort By:
Pageof 5
International Journal of Molecular Sciences|November 13, 2020
AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic LimitationsItalia Falcone, Fabiana Conciatori, Chiara Bazzichetto, et al.Expert Opinion on Therapeutic Targets|August 9, 2011
Emerging pathways and future targets for the molecular therapy of pancreatic cancerVanja Vaccaro, Davide Melisi, Emilio Bria, et al.Current Pharmaceutical Design|October 22, 2013
Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'Sara Pilotto, Maria Bonomi, Francesco Massari, et al.Journal of Cellular Physiology|May 28, 2005
Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growthDaniela Trisciuoglio, Marianna Desideri, Ludovica Ciuffreda, et al.Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 8, 2007
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesGiampaolo Tortora, Roberto Bianco, Gennaro Daniele, et al.Advances in Biological Regulation|August 5, 2014
PTEN expression and function in adult cancer stem cells and prospects for therapeutic targetingLudovica Ciuffreda, Italia Falcone, Ursula Cesta Incani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cellsMichele Milella, Daniela Trisciuoglio, Tiziana Bruno, et al.Frontiers in Oncology|June 20, 2022
Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR InhibitionFabiana Conciatori, Erica Salvati, Ludovica Ciuffreda, et al.Expert Opinion on Pharmacotherapy|March 12, 2013
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicineSara Pilotto, Umberto Peretti, Silvia Novello, et al.Expert Opinion on Investigational Drugs|June 13, 2015
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancerSara Pilotto, Silvia Novello, Umberto Peretti, et al.Pageof 5